A Taiwan-made vaccine for the H7N9 strain of avian flu is expected to begin mass production in June this year after completing human trials, Taichung-based Adimmune Corporation said Thursday.

Adimmune, the only human vaccine producer in Taiwan, said it has completed animal trials and will begin a second phase of human trials for its H7N9 vaccine in March.

One of the world's first GMP vaccine manufacturers to engage in research and development of a vaccine for H7N9, the company said it will be able to produce 3 million doses of the vaccine per month once mass-production has begun.